Imlifidase

Summary

Imlifidase (CHEMBL4297981) is an approved enzyme (ATC L04AA41); indicated across 10 conditions including immune system disorder and anti-glomerular basement membrane disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Enzyme
• ATC class: L04AA41
• Indications: 10 conditions
• Clinical trials: 18

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297981
Name	Imlifidase
Type	Enzyme
Max phase	4
ATC	L04AA41

Also known as: Hmed-ides, HMED-IdeS, HMEDIDES, Idefirix, Ides recombinant, Imlifidasa, Imlifidase, IdeS, IMLIFIDASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

10 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
immune system disorder	4	MONDO:0005046	EFO:0000540
anti-glomerular basement membrane disease	2	MONDO:0009303	EFO:0007290
chronic kidney disease	2	MONDO:0005300	EFO:0003884
graft versus host disease	2	MONDO:0013730	EFO:0004599
autoimmune thrombocytopenic purpura	2	MONDO:0008558	EFO:0007160
Guillain-Barre syndrome	2	MONDO:0016218	EFO:0007292
Duchenne muscular dystrophy	1	MONDO:0010679	MONDO:0010679

3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 18.

Phase distribution

Phase	Trials
PHASE2	11
PHASE3	3
PHASE1	2
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04935177	PHASE3	COMPLETED	Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
NCT05369975	PHASE3	COMPLETED	Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
NCT05679401	PHASE3	TERMINATED	A Study With Imlifidase in Anti-GBM Disease
NCT05753930	PHASE2	RECRUITING	Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
NCT06518005	PHASE2	RECRUITING	Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
NCT02224820	PHASE2	COMPLETED	Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
NCT02475551	PHASE2	COMPLETED	Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation
NCT02790437	PHASE2	COMPLETED	A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
NCT02854059	PHASE2	TERMINATED	IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
NCT03157037	PHASE2	COMPLETED	Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
NCT03897205	PHASE2	COMPLETED	An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
NCT03943589	PHASE2	COMPLETED	A Study of Imlifidase in Patients With Guillain-Barré Syndrome
NCT05049850	PHASE2	TERMINATED	A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
NCT06461546	PHASE2	WITHDRAWN	Imlifidase in Living Donor Renal Transplantation Highly Sensitized Recipients
NCT01802697	PHASE1	COMPLETED	Safety Study on IdeS in Healthy Volounteers
NCT06241950	PHASE1	TERMINATED	A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
NCT03611621	Not specified	COMPLETED	A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
NCT04711850	Not specified	TERMINATED	An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).